Literature DB >> 1878132

Immunotherapy of rheumatic diseases--practice and prospects.

G Kingsley1, G Panayi, J Lanchbury.   

Abstract

Present treatments for rheumatic diseases are both toxic to patients and largely ineffective in modifying the disease process. This report, based on a meeting recently held in London, investigates how far recent molecular and immunological advances can be converted into more effective, less toxic and, above all, more specific therapies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878132     DOI: 10.1016/0167-5699(91)90048-X

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  6 in total

Review 1.  Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention.

Authors:  Z Szekanecz; A E Koch; S L Kunkel; R M Strieter
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

Review 2.  Lupus therapy.

Authors:  H Baart de la Faille
Journal:  Clin Investig       Date:  1994-10

3.  Lymphocyte vaccination prevents spontaneous diabetes in the non-obese diabetic mouse.

Authors:  R A Smerdon; M Peakman; M J Hussain; D Vergani
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

Review 4.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

5.  Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4.

Authors:  J A van Roon; J L van Roy; A Duits; F P Lafeber; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

6.  Evaluation of Antiarthritic Potential of Methanolic Extract of Gentiana kurroo Royle.

Authors:  Khan Mubashir; Bashir A Ganai; Khalid Ghazanfar; Seema Akbar
Journal:  Arthritis       Date:  2014-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.